

The challenging issue with pretransfusion testing of Daratumumab treated patients can possibly be solved by DaraEx

Forfattere: *Katrine Lykke Pedersen, Thure Haunstrup, Jane Vad*
Regional center for Blood Transfusion and Clinical Immunology, University hospital of Aalborg, Denmark

Daratumumab is a monoclonal human anti-CD38 immunoglobulin, which binds CD38, a surface protein, and initiate an immune mediated response against Multiple myeloma cells. Serologically, Daratumumab has a downside. It leads to false reactions in type and screen, crossmatching and antibody identification.

DaraEx is an anti-CD38 antibody neutralizing agent that prevents Daratumumab binding the CD38 protein. Theoretically, this resolves the issue with the false reactions in Daratumumab treated patients. Furthermore, using DaraEx in laboratory workup, it would be possible to detect and identify alloantibodies.

DaraEx is a simple procedure in pretransfusion testing: Erythrocyte suspensions are treated with DaraEx, before plasma from patients in Daratumumab treatment is added. The results showed an elimination of the false reactions caused by Daratumumab. By using DaraEx, it was also possible to identify several antibodies.

DaraEx is an expensive agent, but considering time and expenses, a type and screen test treated with DaraEx is preferable to crossmatching and transfusion with phenotype matched blood.